Ipsen

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies with minimal systemic side effects. Xilio leverages its proprietary geographically precise solutions (GPS) platform to create therapies that are activated specifically within the tumor microenvironment to increase efficacy and reduce adverse effects. As of May 2024, Xilio’s therapy candidates included XTX101 (an anti-CTLA-4 monoclonal antibody), XTX202 (a tumor-activated IL-2), XTX301 (a tumor-activated IL-2βγ), XTX501 (a tumor-activated PD-1/IL2), and tumor-activated cell engagers research programs.Since February 2021, the company has been operating as a public listed company. It is traded on the Nasdaq under the ticker symbol XLO.Key customers and partnershipsXilio Therapeutics collaborates within the pharmaceutical and biotech industry to develop and validate therapies and to advance its clinical trial programs, particularly those that can provide support in further developing and commercializing its pipeline. In March 2024, Xilio signed an exclusive license agreement with Gilead Sciences to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

<div>
 
 Rhythm Pharmaceuticals specializes in developing and commercializing treatments for rare genetic disorders of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl syndrome. The company's flagship product, setmelanotide (branded as IMCIVREE), is an FDA-approved prescription medication for chronic weight management in adults and children aged six and older with specific forms of genetic obesity. The medication targets the melanocortin-4 receptor (MC4R) pathway, crucial in regulating weight and hunger. The company also explores additional therapies like RM-853, a ghrelin O-acyltransferase (GOAT) inhibitor for Prader-Willi syndrome​.
 
 
 Key customers and partnerships
 
 
 Rhythm Pharmaceuticals primarily serves patients with rare genetic disorders of obesity, such as those caused by deficiencies in POMC, PCSK1, LEPR, or those with Bardet-Biedl syndrome. The company's key product, IMCIVREE, is marketed to healthcare professionals and patients in the US and Europe.&nbsp;
 
 
 Funding and financials
 
 
 In April 2024, Rhythm Pharmaceuticals secured USD 150 million through convertible preferred stock financing as part of its strategy to advance the care and development of precision medicines for their specialized market. The funding was to be used to support ongoing clinical trials and the development of new therapies addressing rare genetic disorders of obesity​. 
 
 
 
</div>

BAKX Therapeutics is a provider of cancer treatment.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they  have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.

Akkadeas Pharma was founded in 2007 by ex-top executives of the Italian pharmaceutical industry who decided to become entrepreneurs by putting into fruition their broad experience in this area.   The company started operations in 2008 and is focused in the area of the private healthcare expenditure. It offers a vast target of patients, through their family doctors and specialists, a broad array of pharmaceutical products, food supplements and medical devices to treat symptoms, other disturbances that impact negatively on their daily activities and increase the individual wellbeing.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Until recently, there has been comparatively limited innovation in the field of dermatology, where many companies have focused on the reformulation of existing drugs often resulting in marginal patient benefit. In contrast, Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Biomeasure, Inc., one of four research centers of the Ipsen Group to discover drugs in neuro-endocrinology, needed a multi-product, multi-purpose cGMP facility built on a fast track and a tight budget. Richmond started with a process to identify the goals of all Bio-measure stakeholders, continued with design & engineering coordination, achieved the budget through value engineering, and provided guaranteed costs & schedule. The results: 40,000 sf of cGMP manufacturing space, delivered in a short timeframe on a tight budget.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Ipsen is a global specialty-driven biopharmaceutical company focused on innovation and specialty care. Ipsen develops and commercializes innovative medicines in three key therapeutic areas: oncology, neuroscience, and rare disease. Its dedication to oncology is exemplified by its expanding portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma, and pancreatic cancer.

Ipsen: positive final data in advanced NETs

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

Companies that use radioactive isotopes to develop medication for the treatment of diseases in patients.

Companies that use radioisotopes to develop solutions for the diagnosis of patients. Solutions are typically synthesized for internal use on patients and are employed in tandem with a diagnostic imaging device to identify disease or causes of diseases.

Companies that produce and supply radioisotopes to pharmaceutical companies creating radiopharmaceuticals.

Companies providing support services to radiopharmaceutical-related companies. These include testing services, research, and training.

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div> 

Biotechnology company Ipsen has formed a licensing agreement with Foreseen Biotechnology, obtaining unique worldwide rights to develop, produce, and promote Foreseen's preclinical asset, FS001. The agreement is speculated to be worth approximately USD 1 billion. 

FS001 is an antibody-drug conjugate (ADC) that focuses on an antigen that is overproduced in a variety of solid tumors, identified using Foreseen's proprietary AI-powered platforms. Preliminary research on FS001 has displayed its effectiveness against multiple drug-resistant cancers. Ipsen is now set to undertake Phase I trials and handle the commercialization of FS001 as per the terms of the agreement. 

Ipsen is a global biopharmaceutical company based in France, with a specialty in oncology, rare diseases, and neuroscience. The company's mission is to develop transformative medicines to enhance patient outcomes and meet significant unmet medical requirements. 

</div>

Ipsen

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless